Abstract
Foot-and-mouth disease (FMD) is one of the highest risk factors affecting the animal industry throughout the world. Currently, available commercial FMD vaccines have numerous limitations, such as slow induction and short-term maintenance of antibody titers. Therefore, a novel approach is needed that can induce high neutralizing antibody titers to protect the host in the early stages of FMD virus (FMDV) infection and maintain high antibody titers for long periods after one vaccination dose. There are several T-Consciousness Fields (TCFs), introduced by Mohammad Ali Taheri. TCFs are not matter or energy, so they cannot be measured directly. However, we can evaluate their effects indirectly through several reproducible experiments in the laboratory. The present study aimed to evaluate the effect of Faradarmani CF as a type of the TCFs on FMDV replication, titer, and RNA copy number as well as the humoral immune response against two types of inactivated FMDV vaccines with different adjuvants in rats. Two types of FMD vaccines with different adjuvants (Freund and Alum) were prepared, and then 30 male Wistar rats were immunized with vaccines. Rats were divided into 6 groups (n=5 per group). Four groups of rats were studied using the different combinations of treatments and two groups served as positive and negative controls. Vaccination intervals were every 14 days three times. Serum neutralization test (SN) and Enzyme-linked immunosorbent assay (ELISA) were used to assess changes in antibody levels in the serum samples of rats after each immunization. The results showed that Faradarmani CF induced the replication of the virus in vitro. In addition, antibody levels in treated groups under both Freund adjuvant and Alum adjuvant vaccines increased significantly compared to groups without Faradarmani CF treatment. In conclusion, our data suggest that Faradarmani CF may provide an effective approach to increase the success of immunization and vaccination against FMDV serotype O. It is recommended that the effects of TCFs on different types of vaccines be investigated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.